Sg Americas Securities, LLC I Mab Transaction History

Sg Americas Securities, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	BUY	$3.22 - $4.86 $2,051 - $3,095	637 Added 4.52%	14,723 $62,000
Q3 2022 Oct 31, 2022	SELL	$4.01 - $12.34 $54,323 - $167,169	-13,547 Reduced 49.02%	14,086 $56,000
Q2 2022 Jul 29, 2022	SELL	$8.27 - $18.43 $130,384 - $290,567	-15,766 Reduced 36.33%	27,633 $312,000
Q1 2022 Apr 29, 2022	SELL	$12.54 - $46.93 $1.64 Million - $6.14 Million	-130,826 Reduced 75.09%	43,399 $705,000
Q4 2021 Feb 07, 2022	BUY	$45.28 - $74.5 $6.71 Million - $11 Million	148,109 Added 567.12%	174,225 $8.26 Million

Q3 2021 Nov 01, 2021	BUY	$57.18 - $84.43 $2,172 - $3,208	38 Added 0.15%	26,116 $1.89 Million
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $929,919 - $1.63 Million	19,430 Added 292.27%	26,078 $2.19 Million
Q1 2021 May 13, 2021	BUY	$44.38 - $63.97 $49,173 - $70,878	1,108 Added 20.0%	6,648 $322,000
Q4 2020 Feb 04, 2021	SELL	$32.94 - $47.15 $25,232 - $36,116	-766 Reduced 12.15%	5,540 $261,000
Q3 2020 Nov 09, 2020	SELL	$27.46 - $47.03 $360,137 - $616,798	-13,115 Reduced 67.53%	6,306 $297,000
Q2 2020 Jul 20, 2020	SELL	$13.0 - $31.0 $90,844 - $216,628	-6,988 Reduced 26.46%	19,421 $582,000
Q1 2020 Apr 30, 2020	BUY	$10.63 - $15.37 $280,727 - $405,906	26,409 New	26,409 $343,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $131M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.